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Abstract
Background: Xenotropic murine leukemia virus-related virus (XMRV) was generated after a recombination event between
two endogenous murine leukemia viruses during the production of a prostate cancer cell line. Although the associations of
the XMRV infection with human diseases appear unlikely, the XMRV is a retrovirus of undefined pathogenic potential, able
to replicate in human cells in vitro. Since recent studies using animal models for infection have yielded conflicting results, we
set out an ex vivo model for XMRV infection of human tonsillar tissue to determine whether XMRV produced by 22Rv1 cells
is able to replicate in human lymphoid organs. Tonsil blocks were infected and infection kinetics and its pathogenic effects
were monitored
Results: XMRV, though restricted by APOBEC, enters and integrates into the tissue cells. The infection did not result in
changes of T or B-cells, immune activation, nor inflammatory chemokines. Infectious viruses could be recovered from
supernatants of infected tonsils by reinfecting DERSE XMRV indicator cell line, although these supernatants could not
establish a new infection in fresh tonsil culture, indicating that in our model, the viral replication is controlled by innate
antiviral restriction factors.
Conclusions: Overall, the replication-competent retrovirus XMRV, present in a high number of laboratories, is able to infect
human lymphoid tissue and produce infectious viruses, even though they were unable to establish a new infection in fresh
tonsillar tissue. Hereby, laboratories working with cell lines producing XMRV should have knowledge and understanding of
the potential biological biohazardous risks of this virus.
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Introduction
Xenotropic murine leukemia virus-related virus (XMRV) was
initially identified in some prostate cancer tissues [1] and while
several studies confirmed the presence of the virus in human
prostate cancer cells with similar [2–7], or lower prevalence [8–
10], other authors have reported no evidence of the virus in
patient samples [11–19]. Later, this retrovirus was also detected in
blood samples of a high proportion of individuals with chronic
fatigue syndrome (CFS) [20], in the respiratory tract of patients
with or without a respiratory tract infection [21], and a similar
polytropic murine leukemia viruses (MLV) was found even in
a high proportion of CFS cases [22]. Nevertheless, several
subsequent studies failed to identify XMRV in CFS patients or
healthy donors [23–30], and even blood samples from CFS
patients previously reported to contain XMRV sequences were
retested and were identified as XMRV negative [27,31,32]. These
data have resulted in the retraction of Lombardi et al. and Lo et al.
papers [33–35].
In order to explain the positive results, several studies suggested
that the detection of XMRV sequences in human samples was
a result of contamination of laboratory reagents with mouse DNA
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37415[36–44], with DNA from the chronically infected DU145 cell line
[45,46] or with a XMRV plasmid DNA [33]. Finally, the assertion
that XMRV is circulating in human population has been
challenged by the report showing that XMRV was generated by
a recombination event between two endogenous MLVs during in
vivo tumor passaging in mice [47], which yielded the popular
prostate cancer cell line 22Rv1 [48].
The 22Rv1 (ATCC CRL-2505) cell line was established from
human prostate tumor explants after serially passing through
athymic nude mice around 1991 [48–50] and has been widely
used in laboratory experiments in prostate cancer research with
over 198 citations in PubMed. Electron microscopic analysis of
culture medium from this cell line revealed the presence of
gammaretrovirus-like particles, further identified as a xenotropic
murine leukemia virus-related virus (XMRV) showing multiple
integrated copies and a high-level of viral production [51].
Despite the discovery of the origin of the virus and the
accumulation of data showing that the virus is not present in the
general human population, XMRV is a novel replication-
competent virus and could be a potential human pathogen since
it has been shown to successfully infect many human cell types in
vitro [6,52,53] including PBMCs and neuronal cells [17,54,55].
Indeed, contamination of vertebrate cell lines with retroviruses has
been widely described, being gammaretroviruses the most frequent
contaminants [56–62]. About 60 copies of MLV sequences are
present as endogenous proviruses in mouse genomes [63] from
which up to 15 copies are related to infectious xenotropic murine
leukemia viruses (XMLV) [64]. The XMLV are type C retro-
viruses from mouse which can infect human or other foreign
species [65–67] and have been identified in human cultures
derived after xenografting immune compromised mice [68–71].
Recently, the presence of several MLV strains in over one fourth
of xenograft cell lines has been documented [72], some of them
releasing large number of infectious virions. This is the case of
22Rv1 cells, a high-titer XMRV producing cell line which should
be carefully considered from the standpoint of possible horizontal
spread to other human cells and biohazard of unknown potential
to laboratory personnel [51]. Regarding the virus transmission to
other cell lines, two cell lines that have become infected with
XMRV in the laboratory by a contamination with the 22Rv1cell
line have already been reported, confirming the highly infectious
nature of this virus [72,73]. Concerning the potential biohazards
Figure 1. Detection of proviral XMRV DNA in human lymphoid tissue. DNA was amplified by a single-round conventional PCR using a XMRV
gag specific primer set and the PCR fragments were analysed on a 2% agarose-gel. A) XMRV-gag fragments in isolated tissue cells at the last day of
the experiment in presence or absence of the antiretroviral inhibitors AZT and RAL. B) Proviral DNA content in cells migrating out of the tissue at
different time points over the culture in absence or presence of AZT or RAL. PCR results from a representative experiment are shown.
doi:10.1371/journal.pone.0037415.g001
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important to explore XMRV infectivity and replication capacity in
humans.
The infectivity of XMRV in humans may be strongly limited by
innate host restriction factors such the APOBEC (apolipoprotein B
mRNA-editing catalytic polypeptide) family, which play an
important role in viral tropism, establishment of viral infections
in vivo and successful spread of viruses. The family of APOBEC
proteins, including APOBEC 3G and APOBEC 3F, have been
implicated in the inhibition of a variety of retroviruses (HIV, SIV,
HTLV and MLV) [74–78] and retrotransposons [79,80]. These
proteins are cytidine deaminases, which when incorporated in
viral particles alter the nascent retroviral DNA leading to massive
G-to-A hypermutation of the viral genome [81,82]. In the case of
XMRV, it has been shown that its replication is highly sensitive to
APOBEC proteins and tetherin [52,54,83–85]. XMRV was
hypermutated in A3G/A3F-expressing cell lines and in cultured
human PBMCs, where replication was potently inhibited [54,83].
However, despite these observed in vitro restrictions, infectious
XMRV was recovered from infected PBMCs when cocultured
Figure 2. Quantitative time course of XMRV gag sequences of ex vivo infected tonsillar tissue. Isolated DNA was amplified by quantitative
real-time PCR and the absolute XMRV copy numbers were obtained by normalizing the results with the values obtained with the single copy CCR5
gene in each sample. Each sample was run in duplicate. A) Absolute XMRV DNA content in tissue cells, after 22 days of infection, in the presence or
absence of two antiretroviral drugs, AZT and RAL. B) XMRV DNA content in cells migrating out of the tissue collected from days 2 to 22 post-infection
in the presence or absence of the indicated inhibitors.
doi:10.1371/journal.pone.0037415.g002
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support a productive infection, they may potentially act as a source
of infectious XMRV in vivo [17,54].
In the absence of any known human infection, information
about the infectivity and replication capacity in humans is needed.
Until now, animal models have been used for the study of the
natural history of XMRV infection, although the infection of two
non-human primate species has yielded conflicting results [86,87].
Organ cultures provide a versatile experimental system for
studying the primary events surrounding virus transmission and
the initiation of viral infections in human cells. It has been shown
that human lymphoid tissue cultured ex vivo is a suitable model for
HIV and HHV-6 pathogenesis [88–90]. In this system, HIV-1
infection results in cell activation and massive CD4
+ T-cell
depletion
The present study focuses on the characterization of infection of
XMRV derived from the 22Rv1 cell line in lymphoid tissue ex
vivo. We found that XMRV could infect human lymphoid tissue
and infectious viruses were recovered capable to infect a DERSE
XMRV indicator cell line, despite viral genomes were highly
edited by APOBEC. However, the amount of virus released into
the culture supernatant was not sufficient to establish a new
infection in lymphoid tissue. The infection appears to have no
pathogenic effects in lymphocytic populations or in the level of
inflammatory chemokines, nonetheless, laboratories working with
cell lines producing XMRV should have knowledge and un-
Figure 3. XMRV RNA released by ex vivo human lymphoid tissue infected with 22Rv1 supernatant. Blocks of tonsillar tissues were
infected ex vivo with XMRV from 22Rv1 cells supernatant. Culture medium bathing the tissue blocks was changed every 3–4 days and analysed for the
presence of XMRV RNA using a quantitative real-time RT-PCR. A) Cumulative amount of XMRV RNA released between days 9 and 22 post-inoculation
in infected cultures in the presence or absence of the antiviral drugs AZT and RAL. The graph represents the viral RNA content in two donors (mean 6
SEM). B) Kinetics of XMRV RNA released by infected tonsillar tissue and the effect of the addition of antiviral drugs to the culture.
doi:10.1371/journal.pone.0037415.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37415Figure 4. Hypermutation of XMRV in infected human lymphoid tissue. DNA from tonsillar tissue infected with XMRV was amplified, cloned
and sequenced. A) Graphic representation of the changes (compared to XMRV VP42) presents in the XMRV gag region. The mutations presents in
clones from 5 different donors are shown. Each mutation is denoted by a vertical line marked onto a single horizontal line representing the entire
amplicon, color coded with respect to dinucleotide context: GGRAG (red). GARAA (cyan), GCRAC (green), GTRAT (magenta), and non GRA
(black). Analysis was performed using the HYPERMUT program [91]. B) Preferences of nucleotide substitutions from all the obtained sequences, ‘‘n’’
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virus.
Materials and Methods
Cells, viruses and antiviral agents
22Rv1 cells were obtained from the American Type Culture
Collection (ATCC) and Detectors of Exogenous Retroviral
Sequence Elements (DERSE) XMRV indicator cell line was
kindly provided by Dr. Vineet N. KewalRamani (National Cancer
Institute, Frederick, Maryland, USA). Both cell lines were
maintained in RPMI 1640 medium with 10% FBS (Invitrogen,
Spain). Cell-free XMRV was harvested from 22Rv1 supernatant,
clarified by centrifugation; aliquots were stored at 280uC until
used. Zidovudine (AZT) was purchased from Sigma-Aldrich
(Spain) and Raltegravir (RAL) was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH; from Merck & Company, Inc.
XMRV infection of human lymphoid tissue ex vivo
Human tonsils were obtained from patients undergoing
therapeutic tonsillectomies. All procedures followed the Helsinki
Declaration in 1975, as revised in 1983, and were approved by the
Ethics committee of the Hospital Germans Trias i Pujol. All
individuals provided their written informed consent. The speci-
mens were dissected into ,2–3 mm
3 blocks, and cultured in
RPMI 1640 medium supplemented with 15% fetal bovine serum,
1 mM sodium pyruvate (Invitrogen Life Technologies, Spain),
0.1 mM minimal essential medium with nonessential amino acids
(Invitrogen) and a mixture of antibiotics on top of collagen sponge
gels at the medium-air interface as previously described [88].. Nine
individual blocks were placed on the gelfoam in a well of a six-well
plate. Lymphoid tissue blocks were left uninfected or were infected
with 5 mL of XMRV stock (4610
8 RNA copies/mL) for each
tissue block. Cultures were conducted in the absence or the
presence of reverse transcriptase or integrase inhibitors, AZT
(10 mg/mL) or RAL (5 mg/mL), respectively. Fresh drug was
added at every medium change. Each experimental condition was
composed of three wells for a total of 27 blocks whose culture
media were pooled. Culture medium was harvested every 3–4
days, centrifuged and both, the pellets with the cells migrating out
of the tissue, and the clarified supernatant were frozen at 280C
until use. On days 14 to 22 after infection, cells were mechanically
isolated from uninfected and infected tissue blocks and immuno-
denotes the total number of sequenced base pairs. C) Summary of the observed changes at the different dinucleotide context. ‘‘n’’ denotes the
number of mutations;
aPercentage of the total number of changes;
bPercentage of the number of G-to-A changes.
doi:10.1371/journal.pone.0037415.g004
Figure 5. Lymphocyte populations in uninfected and XMRV infected lymphoid tissue. Tissue cells at day 9 post-infection were isolated,
stained with monoclonal antibodies and analyzed using flow cytometry. Percentages of T (CD4
+ and CD8
+) and B cells in uninfected (XMRV
2) and
XMRV infected (XMRV
+) tissues are shown. Data are means 6 SEM from 5 independent infected tonsils.
doi:10.1371/journal.pone.0037415.g005
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analyses.
XMRV DNA detection
Viral infection was evaluated at different time points in the cells
migrating out of the tissue and in tissue cells at the end of the
culture by analyzing the presence of viral DNA by conventional
PCR. DNA was isolated using QIAamp DNA Blood kit (Qiagen,
Spain) according to the manufacturer’s instructions, and gag gene
was amplified as previously described [20]. Briefly, PCR was
conducted with 5 mL of extracted DNA and the primers 419F and
1154R using Accuprime Taq DNA Polymerase (Invitrogen,
Spain). The cycles were 10 min at 94uC (30 sec at 94uC, 30 sec
at 57uC, 1 min 68uC)640 cycles and 10 min at 68uC. Then,
samples were electrophoresed in 2% agarose gels containing
SYBR safe DNA in TAE buffer.
Quantitative Real-Time PCR
To quantify the absolute XMRV DNA copy numbers, standard
plasmids for XMRV-gag and for the single-copy CCR5 gene were
used. Both plasmids were constructed by conventional PCR using
AmpliTaq High Fidelity (Invitrogen, Spain) and the following
primers: Q445F and Q528R previously described for the detection
of XMRV gag [6] and CCR5-576F (59-TCATTACACCTG-
CAGCTCTCATTT-39) and CCR5-726R (59- ACACCGAAG-
CAGAGTTTTTAGGAT-39) for CCR5 detection. The two PCR
products purified with QIAquick PCR Purification Kit (Qiagen,
Spain) were cloned into a PCR-Script Amp Cloning Kit (Agilent,
Spain) according to the manufacturer’s instructions. The plasmids
were purified by standard methods, their concentrations were
measured using a fluorometer and the corresponding copy
numbers were calculated. Quantitative real-time PCR was
performed with DNA isolated from the cells migrating out the
tissue at different time-point during the culture and in tissue cells
at the end of the culture in duplicate, using a TaqMan Universal
Master Mix (Applied Biosystems, Spain), the primers described
above and the probes: F480PRO; (59-FAM-ACAGAGA-
CACTTCCCGCCCCCG-MGBNFQ-39) and CCR5-661T (59-
VIC-CTGGTCCTGCCGCTGCTTGTCA-TAMRA-39) to de-
tect XMRV gag and CCR5, respectively. A ten-fold serial dilution
of the two standard plasmids, ranging from 1610
10 to 1610
21
copies/reaction was used in duplicate to construct standard curves.
All real-time PCR reactions were performed on a ABI Prism 7000
(Applied Biosystems, Spain).
Quantification of viral RNA released
Quantitative measurements of XMRV viral RNA in culture
supernatants were done using a quantitative real-time RT-PCR
assay. Total RNA was extracted from 280 mL of culture
supernatant at different time points during the culture (QIAamp
Viral RNA kit, Qiagen, Spain) and one-step quantitative reverse
transcription PCR was performed using the Ag-path-ID One-Step
Figure 6. Chemokine production of tonsillar tissues infected ex vivo with XMRV. Tonsillar tissue was infected with XMRV and chemokine
concentrations were measured using Cytometric Bead Array (CBA) in samples of culture medium collected at days 2, 5, 9, 13, 16 and 22. Data are
presented as cumulative amount of released chemokines over the 22 days of culture in the absence or presence of AZT and RAL. Two separate
experiments using two donors were carried out. Data presented are means 6SEM.
doi:10.1371/journal.pone.0037415.g006
XMRV Infects Human Histocultures
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37415XMRV Infects Human Histocultures
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37415RT-PCR Kit from Ambion (Applied Biosystems, Spain) using the
primers, probes and standard curves described above.
G-to-A hypermutation of XMRV proviruses in infected
tissue cells
PCR products obtained by conventional PCR from tissue cells
(see above) were cloned using the PCR-Script Amp Cloning Kit.
Over 10–30 colonies were selected for each product and
sequenced using the Big-Dye Terminator Cycle Sequencing and
the ABI 3100 sequence analyzer (Applied Biosystems, Spain). All
sequences were assembled, aligned and edited using the
Sequencher v.4.2 and GeneDoc v.2.6.001 software. The align-
ments were uploaded to the Hypermut tool on the Los Alamos
National Laboratories website (http://www.hiv.lanl.gov/content/
sequence/HYPERMUT/hypermut.html) to identify hypermu-
tated sequences [91].
Infectivity of newly produced viruses by infected tonsils
To analyze infectivity of supernatants from XMRV-infected
tonsils we used two different approaches. First, infection of the
DERSE XMRV indicator cell line was performed. The de-
velopment of DERSE cells involved the transfection of LNCaPs
cells with a MLV reporter vector encoding puromycin resistance
and a CMV enhancer/promoter driven GFP reporter gene whose
transcription was antisense to the vector mRNA (KewalRamani
VN, unpublished data). DERSE XMRV indicator cells were
plated at a density of 40,000 cells/well in 48-well plates and
allowed to grow overnight. Next day, the cells were infected with
culture supernatant (50 mL) of previous tonsils infected and
harvested at days 16 and 22 post-infection (donor 402). As
a positive control we infected one well with the 22Rv1 supernatant
stock. The culture was splitted at days 3, and 7 and maintained for
10 days. The percentage of GFP-expressing cells was evaluated by
fluorescence microscopy and flow cytometry. In addition, new
tonsils histocultures were re-infected with supernatant harvested at
day 16 and 22 (donor 401 and 402) from previous histocultures
infections. The infection was done at day 0 as described above
although here the tissue was re-infected with the same amount of
virus at day 1 of culture. The culture was maintained 28 days and
culture medium, cells migrating out of the tissue and tissue cells
were harvested as previously described.
Immunophenotypic characterization of tissue
lymphocytes
Single cell suspensions were prepared as described above.
Tissue lymphocytes at the end of the culture were immunophe-
notyped using monoclonal antibodies against the following surface
antigens: CD3, CD4, CD8, CD45RO, CD38 and HLA-DR for
the analysis of T cell, and CD19, IgD, CD38, CD27, from Becton
Dickinson, Barcelona, Spain) and CD10 for B cells (from
eBioscience, Barcelona, Spain). Multicolor analysis was performed
with a LSRII flow cytometer (Becton Dickinson). Data were
acquired with the BD FACSDiva software and analyzed with Flow
Jo software.
Flow cytometric analysis of chemokines
Culture supernatants clarified by centrifugation and collected at
different time points during culture were assayed using a Cyto-
metric Bead Array kit (CBA, BD Biosciences, Spain). Chemokines
(CXCL8/IL-8, RANTES, CXCL9/MIG, CCL2/MCP-1, and
CXCL10/IP-10) were measured using the Human Chemokine kit
according to the manufacturer’s instructions using a LSRII flow
cytometer (Becton Dickinson).
Results
XMRV infection of human lymphoid tissue
To evaluate the ability of XMRV to infect human lymphoid
tissue, infectious XMRV harvested from prostate carcinoma cell
line 22Rv1 was used to infect tonsillar explants ex vivo. After 14
days post-infection, we analyzed the presence of XMRV gag
proviral DNA in tissue blocks. Cells were mechanically isolated
from uninfected and infected tissue and the presence of XMRV gag
proviral DNA was clearly observed in infected tissue cells by
conventional PCR at the end of each experiment (Figure 1A). The
specificity of the infection was evaluated using AZT and RAL, two
antiretroviral drugs known to inhibit XMRV reverse transcriptase
(RT) and integrase, respectively [92,93]. Both drugs completely
inhibited XMRV DNA detection in tissue cells, indicating that
infection is the result of specific reverse transcription and
integration processes (Figure 1A). To assess the kinetics of the
infection we quantified the XMRV proviral DNA in cells
migrating out the tissue, which were collected every 3–4 days.
After 3 days of culture, migrating cells were already XMRV
positive and remained positive until the last day tested (Figure 1B).
The RT inhibitor AZT markedly inhibited the presence of
XMRV proviral DNA in all time points. Conversely, modest
effects were observed after 7 or 14 days in the presence of the
integrase inhibitor RAL (Figure 1B). Cells from the mock-infected
tissue were negative in all cases.
Increase in proviral XMRV DNA content during the
culture of human lymphoid tissue
Once we confirmed the entry and the reverse transcription of
XMRV in the human lymphoid tissue, we accurately evaluated
the level of the infection by setting up a quantitative real-time PCR
to measure the absolute XMRV DNA content. Total XMRV gag
copies per 1610
6 cells were obtained for several tissues by CCR5
normalization after 22 days of infection (Figure 2). A clear increase
in the amount of proviral DNA present in tissue cells was observed
when comparing with the histocultures infected in the presence of
antiretroviral drugs. The treatment with AZT and RAL resulted in
almost complete inhibition (.97%) at most time points and donors
tested (Figure 2A). In migrating cells, the increase in the infection
was detected after 9–10 days of culture, although the proviral
DNA content underwent a significant increase at later points (after
16 days post-infection, Figure 2B). The presence of AZT in the
culture reduced proviral DNA level to negative values from day 3
to the end of cultures. However, in the presence of RAL, proviral
DNA values were comparable to the infected tissue without drug
and remained stable until day 7–13, declining at the last days of
Figure 7. GFP-expression in DERSE XMRV indicator cells infected with tonsil supernatants. DERSE XMRV indicator cells were infected with
tonsil supernatants harvested at day 16 and 22 post-infection (donor 402, see Figure 3B) and with a XMRV stock (22Rv1 supernatant) as positive
control. A) DERSE-GFP positive cells were visualized by conventional phase contrast microscopy and fluorescence microscopy. Phase contrast image
(left panel), GFP fluorescence image (central panel) and GFP/phase contrast merge image (right panel). Data are representative of two independent
experiments. B) Quantitative assessment of DERSE GFP-positive cells. After 7 and 10 days post-infection (D7 p.i. and D10 p.i.) DERSE infected cells
were harvested and the percentage of GFP-expressing cells was analyzed by FACS analysis.
doi:10.1371/journal.pone.0037415.g007
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between both drugs could be explained by the fact that our PCR
system detected not only the integrated DNA, but also un-
integrated DNA. AZT would totally block viral DNA synthesis,
resulting in decrease of both total and integrated DNA. On the
contrary, when an integration inhibitor like RAL is used,
unintegrated viral DNA accumulates in the nuclei in the form of
1-LTR and 2-LTR circles [94]. These episomal forms may explain
the detection of XMRV DNA at an almost constant value over
time in our infected tissue in the presence of RAL.
XMRV RNA detection in the supernatant of infected
histocultures
The observed increase in viral DNA content in both, tissue and
migrating cells, indicated that XMRV might establish a productive
infection in our histoculture model. To evaluate this possibility,
XMRV RNA released into the medium, starting on day 5 post-
infection, was quantified in culture supernatants by using real-time
qRT-PCR. The cumulative production in the infected cultures
from day 9 to day 22 post-infection is shown in Figure 3A. XMRV
RNA was mainly detected in infected tissues that were cultured
without antiviral drugs. The total production of viral RNA in AZT
and RAL containing cultures constituted only the 8 and 4%,
respectively of the infected tissues without drug (Figure 3A). The
evaluation of replication kinetics revealed a decrease in RNA viral
levels up to day 9 in cultures with or without drug, representing
the washing out of the starting viral inoculums (Figure 3B).
Thereafter, RNA virus release experienced a continuous increase
over time in infected tissue without drug from day 9 to the last day
of culture, reaching levels up to 2610
6 copies/mL after 22 days of
culture. This increase in RNA virus release, ranging from 16- to
21-fold in the different tested donors, was completely blocked by
AZT or RAL (Figure 3B). These findings could indicate that
XMRV production, which is sensitive to RT and integrase
inhibitors, occurs in tonsillar tissue.
Host restriction of XMRV in human lymphoid tissue
A severe restriction in the spreading of the XMRV infection has
been shown in PHA-activated human PBMCs [54]. Since human
lymphocytes express restriction factors, such as APOBEC 3G and
3F, [84,95] we sought to determine whether these factors impacted
on XMRV replication in tonsils. DNA from infected tissue cells at
the last day of the experiment was isolated and a 731-base pair
fragment of the XMRV gag region was amplified. The PCR
products were cloned and their DNA sequences were compared to
the XMRV VP42 consensus. A total of 80 clones derived from 5
different donors were analyzed (Figure 4A). An initial analysis
revealed that 46 sequences (57.5%) had mutations, although only
32 (40%) of them harbored more than one mutation. To identify
the hypermutated sequences we used the LANL Hypermut 2.0
program [91], using a p-value,0.05. Compared to XMRV VP42,
a total of 15 (18.8%) sequences were identified as hypermutated,
with a range of 0 to 31.2% among different donors. In total, 180
changes were detected with a mutation frequency of 3610
23/nt
(180 mutations for 58480 nucleotides sequenced) of which 142
were G-to-A changes (Figure 4B). Substitutions in the GG
dinucleotide context (GG-to-AG), which is the specific target site
for APOBEC 3G [81,82], were more prevalent (76%) than in the
APOBEC 3F-preferred context (GA-to-AA) (20%), suggesting that
XMRV in our ex vivo infection is mainly restricted by APOBEC
3G (Figure 4). At the amino acid level, mutations caused both,
changes in the amino acid sequence and introduction of stop
codons.
Pathogenic effects of XMRV infection
To further characterize the XMRV infection in tonsillar tissue,
we investigated possible pathogenic effects. It has been shown that
HIV-1 severely depletes CD4
+ T-cells in ex vivo infected human
lymphoid tissue [88,89], with a depletion of 77 and 97% of CD4
+
T-cells relative to uninfected samples after 8 and 13 days post-
infection, respectively [96]. Therefore, we addressed whether
XMRV replication may alter tissue lymphocytes. Despite the
apparent infection of the tissue, we did not observed changes in the
percentage of the main lymphocyte populations after 9 days of
infection (Figure 5). XMRV infection did not modify the
percentage of CD3
+ T-cells (63611% and 6468% in XMRV
2
and XMRV
+ tissue, respectively), nor CD4
+ T-cells (4767% vs
4865%), nor CD8
+ T-cells (20612% vs 19611%). The
percentages of B cells were also similar between both tissues,
CD19
+ cells (29616% vs 27614%) (Figure 5). A deeper analysis of
T-cell subsets showed that XMRV infection did not modify the
naı ¨ve/memory cell ratio, in both T and B cells, nor immune
activation markers, evaluated by the expression of CD38 and
HLA-DR in both CD4
+ and CD8
+ T-cells (data no shown). None
of these parameters was modified after 28 days in culture (data no
shown).
Release of different chemokines upon XMRV tissue
infection
In human lymphoid tissue infected with other viruses such as
HIV and HHV-6 a modulation in the chemokine secretion by
viral replication has been documented [90,97,98]. To address this
possibility, five chemokines from a designed Human Chemokine
kit, some of them previously described to be altered in patients
with CFS [99,100] were measured by using a quantitative
cytometric bead array on the supernatants collected during the
course of 22 days of viral infection The total production of those
chemokines did not significantly change by XMRV infection in
the absence or presence of antiviral drugs (Figure 6).
Recovery of replication-competent XMRV from
supernatants of infected tonsils
The increase in DNA and viral RNA together with the presence
of hypermutated sequences suggests an active replication. To
evaluate if the supernatant of infected tonsils histocultures
contained replication-competent virus, we performed a viral
infectivity assay using DERSE XMRV indicator cells, which were
infected with those supernatants. The indicator cell line DERSE
XMRV will only produce GFP following infection with a replica-
tion-competent virus since the gfp gene is functionally reconstituted
upon reverse transcription. DERSE cells were infected with 50 mL
of supernatants harvested at day 16 and 22 (donor 402, Figure 3B)
Figure 8. Re-infection of human lymphoid tissue with tonsil supernatants. New histocultures from two different donors were prepared and
infected at day 0 and 1 with a XMRV stock (22Rv1 supernatant) and supernatants harvested at day 16 and 22 post-infection (donor 402, Figure 3B).
The positive control (22Rv1 supernatant) was cultured in the presence or absence of AZT. A) Proviral XMRV DNA analyzed by quantitative real-time
PCR in tissue cells isolated after 28 days post-reinfection. Each sample was run in duplicate. B) Absolute proviral XMRV DNA content in cells migrating
out of the tissue collected from days 7 to 28 post-reinfection. C) Kinetics of XMRV RNA released by lymphoid tissue into the medium analyzed by real-
time qRT-PCR.
doi:10.1371/journal.pone.0037415.g008
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respectively and with XMRV from 22Rv1 supernatant stock
(40,000 copies of RNA) and the GFP expression was monitored by
fluorescence microscopy every 2–3 days of infection. GFP
+ cells
were detected in the control culture (infected with 22Rv1
supernatant stock) as early as 3 days (data not shown) and a high
number of cells were positive at day 7 post-infection (Figure 7A).
At this time, GFP expression was also observed when cells were
infected with the supernatants of infected tonsil, (Figure 7A middle
and lower panels). No GFP expression was detected in mock-
infected cells. To quantify the percentage of cells infected with
each supernatant, DERSE cells were harvested and analyzed by
flow cytometry at different days after infection. At 7 days post-
infection a high number of GFP
+ cells (28%) were detected when
a 22Rv1 supernatant stock was used (Figure 7B). In the infections
with the supernatants from day 16 and 22, and in agreement with
the data observed by microscopy, a lower number of GFP
+ cells
were detected (4% and 7%, respectively), although the levels were
significantly higher than those observed in uninfected wells
(Figure 7B) at day 7. Following culture passage, an increase in
the number of GFP+ cells was observed in all the infections,
reaching similar values in the infections with both supernatant
than in the infection with the 22Rv1 stock (21% and 27% of GFP+
cells with supernatants from day 16 and 22, respectively, and 29%
of GFP+ cells with 22Rv1 supernatant. Figure 7B). The results
from this viral infectivity assay suggested that XMRV viral
particles, which were able to replicate and spread were presents in
the tonsillar supernatants.
Furthermore, we analyze the ability of tonsillar supernatants to
re-infect a new histoculture. In order to maximize the infection,
tissue from two different donors was infected at day 0 and re-
infected with the same amount of virus at day 1. We use each time
45 mL( 5mL for each tissue block) of XMRV 22Rv1 stock (4610
8
copies/mL), donor 402 supernatant day 16 (4.7610
5 copies/mL)
and donor 402 supernatant day 22 (2610
6 copies/mL) (see
Figure 3A). After 28 days of infection we observed a very large
number of copies of proviral DNA in tissue cells infected with
22Rv1 supernatant and almost a total inhibition with AZT.
However, none of the tonsil supernatants used to re-infect the
tissue was able to infect this new tissue and only a residual amount
of proviral DNA (even lower than that detected in the infection of
22Rv1+AZT) was observed, mainly in the supernatant from day
22 (Figure 8A). Consistent with the lack of detection of proviral
DNA in tissue cells, we found only a residual level of both, proviral
DNA in cells migrating out of the tissue (Figure 8B) and XMRV
RNA released into the medium (Figure 8C).
Discussion
During the last year an enormous amount of data about the
origin and the prevalence of XMRV have indicated that this virus
has a recombinant origin and it is not circulating in the human
population [11–17,23–33,36–47], although many questions about
the biology and physiopathology of this virus remain still unclear.
Despite all these data and considering, i) the susceptibility of
humans cells to the XMRV infection [53,101,102], ii) the
contradictory data on experimental infection of macaques by
XMRV [86,87], iii) the high-titer production of XMRV by the
22Rv1 cell line, widely used in laboratory, and iv) the existence of
XMRV/human contacts in laboratory personnel involved in cell
culture facilities, it could be relevant to develop new experimental
models for the study of XMRV pathogenesis in humans
alternative to the use of non-human primates.
The main objective of the present study was to investigate
whether the human lymphoid tissue might be a target for XMRV
derived from 22Rv1 supernatant. We used histocultures of human
tonsillar tissues that have been reported as a useful model for
studying various aspects of the pathogenesis of other viruses
[88,90,103]. The ex vivo infection with XMRV allowed us to assess
the replication of the virus, in addition to the pathogenic effects of
this infection in human lymphoid tissue.
Tonsillar tissue after 14–22 days of infection become efficiently
and specifically infected by XMRV. In contrast to previously
described findings using in vitro infected PBMCs, the proviral copy
numbers in our ex vivo infected histoculture increased overtime
from day 2 to day 22 which could indicate that new target cells
become infected throughout the culture. This increase in the
proviral DNA content was concomitant to the increase in XMRV
RNA released into the culture medium, suggesting that this
XMRV RNA is associated with infectious particles that may lead
to the spread of the infection. When the presence of infectious viral
particles in the supernatants of infected tonsils was evaluated, we
observed that we could recover replication-competent XMRV
from these supernatants by infecting the indicator DERSE XMRV
cell line. In contrast, those supernatants were unable to establish
an infection in fresh lymphoid tissue, suggesting that with the
passage of the virus through several rounds of infection, the innate
antiviral restriction factors may abrogate its infectivity. Neverthe-
less, it should be noted that these supernatants have a much lower
amount (2 to 3 log-copies of RNA/mL less) that the 22Rv1
supernatant used as a positive control of infection. Indeed, a high
viral titer is required to establish an infection in human PBMCs
[17,54], so it is possible that viruses released by tonsils, although
infectious in the DERSE assay, did not reach a sufficient titer to
establish a new histoculture infection. In addition, the increase in
proviral copy numbers, both in the tissue and the migrating cells,
could be fully explained by cell divisions of infected cells, which in
turn would lead to an increase in the level of released XMRV
RNA.
Although the absolute levels of XMRV RNA released varied
from donor to donor, the replication was similar to those observed
in tonsillar tissue infected with some strains of HIV (R5 strains)
(ranging between 2 and 5610
6 RNA copies/mL) [97], but lower
than viral production of more pathogenic strains of HIV (64
strains), which range from 15 to 60610
6 RNA copies/mL [97].
However, for HIV has never been reported whether this amount
of virus produced is sufficient to establish a new productive
infection in a new histoculture.
Our observation that we could not establish a new infection in
tonsillar tissue may indicate that, in ex vivo infected human
lymphoid tissue, the virus is restricted by innate host restriction
factors such the APOBEC family, since hypermutation, the
introduction of excessive G-to-A substitutions by those host
proteins that impair the viral replication, has also been observed
in our experimental model. The sequence analysis of our clones
showed that 19% of the sequences were hypermutated. This
percentage, although lower than the 77 and 65% of hypermutated
sequences found with the infection of two APOBEC 3G/3F
positive cell lines (CEM and H9, respectively) [83], is similar with
the level of hypermutagenesis described in the infection of PHA-
stimulated PBMCs [54]. In addition, the mutation frequencies
obtained from our sequences (3610
23/nt) were higher than those
found in 22Rv1 proviral DNA (4.9610
24/nt) or with the infection
of an APOBEC 3G/3F negative cell (CEM-SS) (8.4610
24/nt),
although they were similar to those found in the infection of H9
cells (6.6610
23/nt) [83]. Moreover, although G-to-A mutations
can occur in one of four different dinucleotide contexts (GG, GA,
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GA-to-AA changes [81], while APOBEC 3F primarily induce GA-
to-AA [76]. In tissue, most of the G-to-A changes occurred in a GG
dinucleotide context. Overall, our data indicate that XMRV
infection would be restricted, mainly by APOBEC 3G, as
described in in vitro infected PBMCs or human cell lines.
Nonetheless, in lymphoid tissue, the virus could somehow be able
to evade or overcome these restriction factors, as a low amount of
infectious virus is released. There are various non-excluding
explanations for this observation. The most obvious conjecture
could be that the level of APOBEC 3G is lower in lymphoid tissue
than in peripheral PBMCs and not enough to block virus
replication. However, all APOBEC family members are expressed
widely in hematopoietic cell populations and in tissues, particularly
in tonsils [95]. Secondly, despite the fact that our data show that
mechanically isolated lymphocytes from tissue and migrating cells
are XMRV DNA
+, the cell population responsible for the viral
production remains unknown. In our histocultures, XMRV could
infect other cell types that do not express these restriction factors,
being a non-lymphoid cell the major viral target as it was shown in
prostate cancer tissues [3] or in tissues from experimentally
infected monkeys [86]. Further work is necessary to define the
cellular population that would sustain this low viral production in
ex vivo infected tonsils.
In ex vivo HIV infected tonsils, virus replication causes a pro-
found depletion of the viral target cells (CD4
+ T cells). In our
histocultures, we did not observe changes in the percentages in any
of the major lymphocyte populations or modifications in the
release of inflammatory chemokines. Yet, in XMRV infected
macaques the virus did not induce any lymphocyte depletion,
rather there was an increase in the frequency of circulating B and
NK cells in blood [86].
In conclusion, in the absence of any confirmed human XMRV
infection and with the conflicting results of infection in animal
models, which may not accurately mimic human XMRV in-
fection, in our ex vivo cultured human lymphoid tissue, XMRV is
able to infect tissue cells and produce infectious viruses, even
though they were unable to establish a new infection in fresh
tonsillar tissue. The XMRV replication is largely controlled by
innate antiviral restriction factors and probably further contained
by the adaptative immune response, although the long term
presence of proviral DNA and viral RNA in the lymphoid tissue
remains absolutely unknown. Hereby, laboratories working with
XMRV producing cell lines should be aware of the potential
biohazard risk of working with this replication-competent retro-
virus.
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